ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 5, 2017
The Bull Case for Airline Stocks?
Image Source: BriYYZ. Warren Buffett has famously said that airline stocks are horrible long-term investments, but his vast portfolio now owns a number of airlines. What’s the bull case for owning these capital-intensive, cyclical and often boom-and-bust stocks?
Oct 5, 2017
The Legal Battle Between Regeneron and Amgen Heats Up
Image Source: Regeneron. The legal battle between two of the titans of the biotech world heated up further with a recent ruling overturning the injunction of a critical asset. We are updating our thesis in light of current events.
Oct 2, 2017
Verint Systems: An Overlooked Idea on Cybersecurity
Image Source: Verint. The Best Ideas Newsletter idea is trying to break through the mid-$40s level, which has been illusive since late 2015.
Sep 30, 2017
Will Texas Tea Hit $75 Per Barrel By Year’s End?
Image Shown: The performance of the VanEck Vectors Oil Refiners ETF (CRAK) since its launch in August 2015.We’ve witnessed our fair share of fits and starts from energy resource prices during the past few years, but could the global crude markets finally be rebalancing? Let’s talk about our thoughts on whether the outlook for energy resource pricing is improving in a sustainable way.
Sep 29, 2017
Our Reports on Stocks in the For-Profit Education Industry
Image Source: GotCredit. Our reports on constituents in the For-Profit Education industry can be found in this article. Reports include ATGE, BPI, CECO, CPLA, EDU, LOPE, LRN, STRA, UTI.
Sep 24, 2017
Dividend Increases/Decreases for the Week Ending September 22
Let's take a look at companies raising/lowering their dividends this week.
Sep 24, 2017
How Strong Is Caterpillar’s 2.5% Dividend Yield?
Image Shown: A 10+ year share-price chart of Caterpillar. The stock has recently set new all-time highs.Caterpillar’s stock has reached new all-time highs! How excited should income investors be?
Sep 22, 2017
Best in Biotech? Global Blood Therapeutics' Promising Treatment for Sickle Cell Anemia
Image Source: National Institute for Health. We remain impressed with the depth of research conducted over a wide host of disease states. Though a molecule may appear to hold significant promise in the pre-clinical phase, we have often witnessed the unique ability of the human body to react to various treatments. Often an unwanted side effect can torpedo a treatment, thus relegating millions of dollars of research obsolete. However, if a promising molecule is brought to market, the payoff is often well worth the effort. Our goal is to sift through the various clinical data to unearth the most promising treatments with the understanding that nothing is assured until the FDA authorizes the product for marketing in the US. We believe we have identified a promising junior biotech in the rare drug field with a promising treatment for sickle-cell anemia.
Sep 21, 2017
The Asset Sales at Teva Have Begun
Image Source: Teva. We continue to watch the implosion of Teva with some interest; the company was once a Best Ideas Newsletter portfolio idea thanks to its strong ability to generate a copious amount of free cash flow. However, Teva made the classic mistake of purchasing a company that operates in a highly-commoditized industry at a market top while loading up the balance sheet with an enormous amount of debt at the precise time the favorable industry dynamics began transitioning to a headwind. Let’s review the company’s progress for signs of a turnaround.
Sep 17, 2017
Dividend Increases/Decreases for the Week Ending September 15
Let's take a look at companies raising/lowering their dividends this week.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.